PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.

MLA

Marco-Benedí, Victoria, et al. “PCSK9 Inhibitors on the Management of Primary and Secondary Cardiovascular Prevention.” Lipids in Health & Disease, vol. 23, no. 1, Sept. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12944-024-02283-x.

APA

Marco-Benedí, V., Sánchez-Hernández, R. M., Díaz, J. L., Jarauta, E., Suárez-Tembra, M., Pintó, X., Morillas, C., Plana, N., Pedro-Botet, J., & Civeira, F. (2024). PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention. Lipids in Health & Disease, 23(1), 1–10. https://doi.org/10.1186/s12944-024-02283-x

Chicago

Marco-Benedí, Victoria, Rosa M. Sánchez-Hernández, José Luis Díaz, Estíbaliz Jarauta, Manuel Suárez-Tembra, Xavier Pintó, Carlos Morillas, Núria Plana, Juan Pedro-Botet, and Fernando Civeira. 2024. “PCSK9 Inhibitors on the Management of Primary and Secondary Cardiovascular Prevention.” Lipids in Health & Disease 23 (1): 1–10. doi:10.1186/s12944-024-02283-x.